The Weekly Recap 1/9/2026: LSI Alumni Achievements Driving Medtech and Healthtech Forward

In a successful week for the medical technology companies in the LSI Alumni community, we saw LSI Alumni secure new funding, appoint new executives, and much more on the road to LSI USA ‘26 in Dana Point (March 16-20).

AccurKardia

Announced FDA 510(k) clearance and the commercial launch of its AccurECG™ Analysis System (v2.0). AccurECG 2.0 builds on AccurKardia’s previously FDA-cleared AccurECG platform, representing the next-generation evolution of the company’s enterprise-grade ECG interpretation system.

Amsel Medical

Announced the appointment of Jeff Carr, MD, as Chief Medical Advisor, strengthening the company’s clinical, regulatory, and advocacy expertise. Dr. Carr brings decades of experience as a physician leader, clinical innovator, and national advocate for outpatient endovascular medicine.

BrainSpace

Received FDA 510(k) clearance for Intellidrop, an automated brain fluid management system integrating proprietary hardware and software to achieve continuous brain pressure measurement and closed-loop, gravity-driven, precision drainage of brain fluid to a personalized volume or pressure goal.

BrightHeart

Announced the closing of an €11 million Series A financing round co-led by Odyssée Venture and GO Capital, with participation from the Mussallem CHD Alliance, Lift Value, IDAHO HealthTech Club via Side Angels, and founding investor Sofinnova Partners, as well as prominent clinicians and angel investors. This financing will support U.S. commercialization, expansion across Europe, and relentless product innovation, scaling the B-Right AI Platform to set a new global standard of care in prenatal ultrasound.

Butterfly Medical

Successfully completed the final 12-month follow-up for all patients in its international pivotal clinical study. The landmark study is designed to evaluate the safety and efficacy of the Butterfly Prostatic Retraction Device, a first-line interventional therapy (FIT) for BPH.

Capstan Medical

Appointed Marshall Mohr to its Board of Directors to further advance the company's mission of bringing its innovative structural heart solution to market and making treatment more accessible to patients. Mohr joined Intuitive Surgical in 2006 as Senior Vice President and Chief Financial Officer, leading the company through a period of exceptional growth.

CMR Surgical

Received CE and UKCA Marks for its Versius Surgical System in paediatric surgery, marking the Company’s first regulatory clearance for treating children. Versius is a unique, versatile and adaptable surgical robot designed to seamlessly and easily integrate into any operating room and hospital workflow.

Cooler Heads Care

Appointed Lauria Sandberg as the new Vice President of Market Access and Reimbursement. The company is the creator of Amma™, an FDA-cleared scalp cooling system designed to help cancer patients reduce hair loss during chemotherapy.

eCential Robotics

Entered into a strategic partnership with Nexxt Spine by combining Nexxt Spine’s implant expertise with eCential’s advanced navigation platform. The two companies are working together to introduce a new app that enhances the way spine procedures are planned and performed.

FineHeart

Announced the completion of a €35 million first closing of its Series C financing round and an additional €48 million in grants from the IPCEI Tech4Cure program. The company’s FlowMaker® is the world’s first fully implantable cardiac output accelerator designed to treat advanced heart failure.

Life Seal Vascular

Announced the successful treatment of two patients in Japan using its investigational Cygnum™ Aneurysm Sac Management Device (ASMD) under compassionate-use authorization. The Cygnum™ device lines the aneurysm sac prior to deployment of the EVAR graft and is designed to prevent type II endoleaks and reduce the need for reintervention in the long-term.

Luminate Medical

Raised $21 million in an expanded Series A round co-led by ARTIS Ventures and Lachy Groom with participation from Western Alliance Life Sciences alongside existing investors 8VC, Y Combinator, Atlantic Bridge, Faber, SciFounders, and others. The company plans to use the new funds to launch access to home cancer care at 40 partner oncology clinics before launching its novel patient-led home infusion technology in mid-2026.

Neurosom

Announced an oversubscribed bridge round led by Portland Seed Fund’s Intrepid Oregon Fund with major participation from the Loomis Family Trust, OEN Angel Syndicate, and ONAMI. The funds will be strategically deployed to scale operations and support additional clinical trials targeting MCI.

Nia Therapeutics

Announced publication in Brain Stimulation of the first in vivo validation of its Smart Neurostimulation System (SNS). SNS is a a wireless, implantable brain-computer interface designed for closed-loop treatment of memory disorders.

Picard Medical

Announced its plans to launch a new, FDA-cleared artificial heart accessory. The company plans to now incorporate the CPC1 “Connector Covers” into its TAH design. It developed this feature to provide comfort during daily activities, while reinforcing system safety and reliability. Picard expects to integrate the new feature and begin its rollout into standard clinical practices in the U.S. on Jan. 15.

Prana Surgical

Announced the completion of the first five clinical procedures using the Prana System™ as part of its early feasibility study in Australia. The Prana System™ has been developed to enable image-guided, minimally invasive surgery, conserving healthy tissue and driving personalized treatment plans in a range of conditions, including lung cancer.

ReGelTec

Appointed Peter Boyd as CEO of ReGelTec. He has been with the company since 2019, serving as General Counsel and Strategic Advisor, and most recently as Executive Vice President of Business Development since 2024.

Sensydia

Announced that the American Medical Association (AMA) has published a new industry-first Category III CPT® code, 1036T, for noninvasive augmentative AI hemodynamic assessment, encompassing Sensydia's Cardiac Performance System (CPS™). The CPS platform uses proprietary non-invasive sensors and artificial intelligence algorithms to assess in real-time key hemodynamic parameters, providing clinicians with actionable data to manage heart failure and pulmonary hypertension patients without invasive catheterization.

Somavac

Closed its $3 million oversubscribed Series A funding round. In addition, the company has added 2 new pilot centers in California and Virginia, and is expanding commercialization by hiring direct sales reps with experience in plastic surgery. Somavac’s FDA-cleared novel negative pressure therapy is helping to reduce complications such as seroma and infection in breast cancer surgery by promoting healing and continuously evacuating fluid in the post-surgical space.

Spiro Medical

Announced the closing of a $67 million Series A funding round led by Andera Partners, Omega Funds, and Sherpa Healthcare Partners, and joined by HSG, Supernova Invest, Northern Light Venture Capital, and Hero Inc. Ltd UK. Proceeds from the financing will be used to develop a purpose-built PNM system and to execute on the clinical work required for regulatory approval in the United States.

SurgiBox

Announced the appointment of Kelly Laurel as President and Chief Executive Officer. Laurel, who has served as the company's Chief Operating Officer for the past year, will succeed co-founder Dr Mike Teodorescu, DBA, who is stepping down as CEO to focus on his academic work and additional research endeavors while continuing to advise SurgiBox as a Board Member.

Tensive

Announced top-line results from a pivotal trial evaluating the REGENERA™ implant in patients undergoing lumpectomy to treat malignant lesions. The new data underscore the minimally invasive device’s potential to allow the body to reconstruct its own breast tissue.

ViCentra

Announced the second close of its Series D financing round, adding $13 million and increasing the total round to $98 million. With this funding, ViCentra will scale manufacturing, deepen commercial execution in Germany, the Netherlands, and France, and accelerate preparations for its next-generation Kaleido insulin patch pump for U.S. market access.

Vivasure

Announced the company has been acquired by Haemonetics Corporation (NYSE: HAE) in a transaction valued up to €185M (~$215M) on completion of certain milestones. Vivasure is focused on the development of advanced polymer implants and delivery systems, primarily focused on minimally invasive vessel closure in cardiology, interventional radiology, and vascular surgery.

Stay tuned for more updates, insights, and achievements of our LSI Alumni in The Weekly Recap, and follow our blog for the latest medical device news and advancements.